N-[(1-乙基-2-吡咯烷基)甲基]乙胺 | 82935-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-[(1-乙基-2-吡咯烷基)甲基]乙胺
• 英文名称: 2-<(ethylamino)methyl>-1-ethylpyrrolidine
• 英文别名: 2-N-ethylaminomethyl-1-ethylpyrrolidine；N-[(1-ethylpyrrolidin-2-yl)methyl]ethanamine
• CAS: 82935-39-5
• 化学式: C₉H₂₀N₂
• mdl: MFCD08361566
• 分子量: 156.271
• InChiKey: VXZJMCUARPMTDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-[(1-乙基-2-吡咯烷基)甲基]乙胺 、 3,5-Dibrom-2,6-dimethoxybenzoesaeurechlorid 以 丁酮 为溶剂， 反应 0.25h， 生成 2-<(N-ethyl-3,5-dibromo-2,6-dimethoxybenzamido)methyl>-1-ethylpyrrolidine
  参考文献：
  名称：

  Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities

  摘要：

  A series of some novel N-(l-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat. Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat. The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration. The structure-activity relationships are discussed.

  DOI：

  10.1021/jm00353a003
• 作为产物：
  描述：

  N-乙基-2-氨甲基吡咯烷 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 8.0h， 生成 N-[(1-乙基-2-吡咯烷基)甲基]乙胺
  参考文献：
  名称：

  Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities

  摘要：

  A series of some novel N-(l-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat. Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat. The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration. The structure-activity relationships are discussed.

  DOI：

  10.1021/jm00353a003

文献信息

• Nitrogen-containing heterocyclic compound
  申请人：Murakata Chikara

  公开号：US20090054407A1

  公开（公告）日：2009-02-26

  The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): wherein W represents a nitrogen atom or —CH—; X represents —C(═O)— or —CHR 4 — (wherein R 4 represents a hydrogen atom, or the like); R 1 represents a group represented by the following formula: [wherein Q 1 represents a nitrogen atom or —CR 8 — (wherein R 8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q 2 represents —NR 15 — (wherein R 15 represents a hydrogen atom, or the like) and R 5 and R 6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R 2 and R 3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种含氮杂环化合物，其由式(I)表示：其中W代表氮原子或—CH—；X代表—C(═O)—或—CHR4—（其中R4代表氢原子或类似物）；R1代表由以下式表示的基团：[其中Q1代表氮原子或—CR8—（其中R8代表氢原子、取代或未取代的低级烷基或类似物）。Q2代表—NR15—（其中R15代表氢原子或类似物），R5和R6可以相同也可以不同，每个代表氢原子、取代或未取代的低级烷基或类似物]；R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的低级烷基或类似物}或其药学上可接受的盐等。
• Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof
  申请人：WISSNER Allan

  公开号：US20080293712A1

  公开（公告）日：2008-11-27

  The present invention relates to Benzo[c][2,7]naphthyridine Derivatives, compositions comprising an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for modulating PDK-1 activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c][2,7]naphthyridine Derivative.

  本发明涉及苯并[c][2,7]萘啉衍生物，包含有效量苯并[c][2,7]萘啉衍生物的组合物，用于治疗或预防增殖性疾病或自身免疫疾病的方法，包括向需要治疗的受体内给予有效量的苯并[c][2,7]萘啉衍生物，用于调节PDK-1活性、PKA活性、Akt活性、S6K活性或PKC活性的方法，包括向需要治疗的受体内给予有效量的苯并[c][2,7]萘啉衍生物。本发明还涉及制备苯并[c][2,7]萘啉衍生物的过程。
• 10a-Azalide Compound
  申请人：Sugimoto Tomohiro

  公开号：US20090281292A1

  公开（公告）日：2009-11-12

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  【目标】提供一种具有新结构的化合物，对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物，其化学式为（I），其药学上可接受的盐或其溶剂化物，或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性，因此可以作为治疗传染病的药物。
• Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation
  申请人：Edlin Christopher

  公开号：US20070191426A1

  公开（公告）日：2007-08-16

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.

  化合物I式或其药学上可接受的盐是磷酸二酯酶IV型（PDE4）的抑制剂，可用于治疗炎症和/或过敏性疾病。
• 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
  申请人：CARAYON Pierre

  公开号：US20090156574A1

  公开（公告）日：2009-06-18

  The invention relates to 2-acylamino-4-phenylthiazole derivatives of general formula (I): pharmaceutically acceptable acid-addition salts thereof, hydrates or solvates of such derivatives or such pharmaceutically acceptable acid addition salts, intermediates thereto, processes for the preparation thereof, and therapeutic application thereof.

  本发明涉及通式(I)的2-酰胺基-4-苯基噻唑衍生物：其药学上可接受的酸加成盐，这种衍生物或这种药学上可接受的酸加成盐的水合物或溶剂合物，其中间体，其制备方法以及其治疗应用。